Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer

Diseases of the Colon and Rectum

Volumn 56, Issue 2, 2013, Pages 142-149

  Duldulao, Marjun P ^a   Lee, Wendy ^a   Streja, Leanne ^a   Chu, Peiguo ^a   Li, Wenyan ^a   Chen, Zhenbin ^a   Kim, Joseph ^a   Garcia Aguilar, Julio ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bowel wall; Neoadjuvant chemoradiation; Rectal cancer; Residual cancer cells

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE WALL; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; RECTUM CANCER; RECTUM CARCINOMA; SECONDARY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT RESPONSE; TUMOR REGRESSION; ADENOCARCINOMA; ADJUVANT THERAPY; CYTOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIATION DOSE; RECTUM TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS;

MLCS; MLOWN;

EID: 84874409211     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e31827541e2     Document Type: Article

References (40)

1. Medich D, McGinty J, Parda D, et al. Preoperative chemoradiotherapyand radical surgery for locally advanced distal rectaladenocarcinoma: pathologic findings and clinical implications.Dis Colon Rectum. 2001;44:1123-1128.
2. Sauer R, Becker H, Hohenberger W, et al. German Rectal CancerStudy Group. Preoperative versus postoperative chemoradiotherapyfor rectal cancer. N Engl J Med. 2004;351:1731-1740.
3. García-Aguilar J ,Hernandez de Anda E, Sirivongs P, Lee SH,Madoff RD, Rothenberger DA. A pathologic complete responseto preoperative chemoradiation is associated with lower localrecurrence and improved survival in rectal cancer patients treatedby mesorectal excision. Dis Colon Rectum. 2003;46:298-304.
4. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome inpatients with a pathological complete response after chemoradiationfor rectal cancer: a pooled analysis of individual patientdata. Lancet Oncol. 2010;11:835-844.
5. Habr-Gama A, Perez RO. Non-operative management ofrectal cancer after neoadjuvant chemoradiation. Br J Surg.2009;96:125-127.
6. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versusnonoperative treatment for stage 0 distal rectal cancerfollowing chemoradiation therapy: long-term results. AnnSurg. 2004;240:711-717.
7. Smith FM, Waldron D, Winter DC. Rectum-conserving surgeryin the era of chemoradiotherapy. Br J Surg. 2010;97:1752-1764.
8. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J.Complete clinical response after preoperative chemoradiationin rectal cancer: is a ";wait and see"; policy justified? Dis ColonRectum. 2008;51:10-19.
9. O'Neill BD, Brown G, Heald RJ, Cunningham D, Tait DM.Non-operative treatment after neoadjuvant chemoradiotherapyfor rectal cancer. Lancet Oncol. 2007;8:625-633.
10. Glynne-Jones R, Hughes R. Critical appraisal of the 'wait andsee' approach in rectal cancer for clinical complete respondersafter chemoradiation. Br J Surg. 2012;99:897-909.
11. Cho YB, Chun HK, Kim MJ, et al. Accuracy of MRI and 18FFDGPET/CT for restaging after preoperative concurrentchemoradiotherapyfor rectal cancer. World J Surg.2009;33:2688-2694.
12. Denecke T, Rau B, Hoffmann KT, et al. Comparison of CT, MRIand FDG-PET in response prediction of patients with locallyadvanced rectal cancer after multimodal preoperative therapy:is there a benefit in using functional imaging? Eur Radiol.2005;15:1658-1666.
13. Jonas J, Bähr R. Neoadjuvant chemoradiation treatmentimpairs accuracy of MRI staging in rectal carcinoma. Gut.2006;55:1214-1215.
14. Smith FM, Chang KH, Sheahan K, Hyland J, O'Connell PR,Winter DC. The surgical significance of residual mucosal abnormalitiesin rectal cancer following neoadjuvant chemoradiotherapy.Br J Surg. 2012;99:993-1001.
15. Garcia-Aguilar J, Chen Z, Smith DD, et al. Identificationof a biomarker profile associated with resistance to neoadjuvantchemoradiation therapy in rectal cancer. Ann Surg.2011;254:486-492.
16. Edge SB, Compton CC, Fritz AG, et al. American Joint Committeeon Cancer (AJCC) Cancer Staging Manual. 7th ed. Chicago,IL: Springer, Inc; 2010.
17. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P,Krieg RM; Timing of Rectal Cancer Response to ChemoradiationConsortium. Optimal timing of surgery after chemoradiationfor advanced rectal cancer: preliminary results of amulticenter, nonrandomized phase II prospective trial. AnnSurg. 2011;254:97-102.
18. Garcia-Aguilar J, Marcet J, Coutsoftides T, et al. Impact of neoadjuvantchemotherapy following chemoradiation on tumorresponse, adverse events, and surgical complications in patientswith advanced rectal cancer treated with TME. J Clin Oncol.2011;29(suppl):abstract 3514.
19. Washington MK, Berlin J, Branton PA, et al. Cancer Committee,College of American Pathologists. Protocol for the examinationof specimens from patients with primary carcinomas of the colonand rectum. Arch Pathol Lab Med. 2008;132:1182-1193.
20. M eterissian S, Skibber J, Rich T, et al. Patterns of residual diseaseafter preoperative chemoradiation in ultrasound T3 rectalcarcinoma. Ann Surg Oncol. 1994;1:111-116.
21. Borschitz T, Wachtlin D, Möhler M, Schmidberger H, JungingerT. Neoadjuvant chemoradiation and local excision for T2-3rectal cancer. Ann Surg Oncol. 2008;15:712-720.
22. Nair RM, Siegel EM, Chen DT, et al. Long-term results oftransanal excision after neoadjuvant chemoradiation for T2and T3 adenocarcinomas of the rectum. J Gastrointest Surg.2008;12:1797-1805.
23. Bedrosian I, Rodriguez-Bigas MA, Feig B, et al. Predicting thenode-negative mesorectum after preoperative chemoradiationfor locally advanced rectal carcinoma. J Gastrointest Surg.2004;8:56-62.
24. Hughes R, Glynne-Jones R, Grainger J, et al. Can pathologicalcomplete response in the primary tumour following pre-operativepelvic chemoradiotherapy for T3-T4 rectal cancer predictfor sterilisation of pelvic lymph nodes, a low risk of local recurrenceand the appropriateness of local excision? Int J ColorectalDis. 2006;21:11-17.
25. Onaitis MW, Noone RB, Fields R, et al. Complete response toneoadjuvant chemoradiation for rectal cancer does not influencesurvival. Ann Surg Oncol. 2001;8:801-806.
26. Dutrillaux B. Pathways of chromosome alteration in humanepithelial cancers. Adv Cancer Res. 1995;67:59-82.
27. Masramon L, Vendrell E, Tarafa G, et al. Genetic instability anddivergence of clonal populations in colon cancer cells in vitro.J Cell Sci. 2006;119(pt 8):1477-1482.
28. M arusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity:A looking glass for cancer? Nat Rev Cancer. 2012;12:323-334.
29. H lubek F, Brabletz T, Budczies J, Pfeiffer S, Jung A, KirchnerT. Heterogeneous expression of Wnt/beta-catenin target geneswithin colorectal cancer. Int J Cancer. 2007;121:1941-1948.
30. Prall F. Tumour budding in colorectal carcinoma. Histopathology.2007;50: 151-162.
31. Karamitopoulou E, Zlobec I, Panayiotides I, et al. Systematicanalysis of proteins from different signaling pathways in thetumor center and the invasive front of colorectal cancer. HumPathol. 2011;42:1888-1896.
32. Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J. Intratumorgenetic heterogeneity in advanced human colorectaladenocarcinoma. Int J Cancer. 2001;93:346-352.
33. Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expressionof putative cancer stem cell markers CD133, CD166,CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer.2010;103:382-390.
34. Kajiwara Y, Ueno H, Hashiguchi Y, et al. Heterogeneity ofmetalloproteinase expression in colorectal cancer: relationof molecular findings to basic morphology. Anticancer Res.2011;31:1567-1575.
35. E yler CE, Rich JN. Survival of the fittest: cancer stem cellsin therapeutic resistance and angiogenesis. J Clin Oncol.2008;26:2839-2845.
36. I shii H, Iwatsuki M, Ieta K, et al. Cancer stem cells and chemoradiationresistance. Cancer Sci. 2008;99:1871-1877.
37. L e NH, Franken P, Fodde R. Tumour-stroma interactions incolorectal cancer: converging on beta-catenin activation andcancer stemness. Br J Cancer. 2008;98:1886-1893.
38. H oogsteen IJ, Marres HA, van der Kogel AJ, Kaanders JH. Thehypoxic tumour microenvironment, patient selection andhypoxia-modifying treatments. Clin Oncol (R Coll Radiol).2007;19:385-396.
39. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, andlocation of immune cells within human colorectal tumorspredict clinical outcome. Science. 2006;313:1960-1964.
40. N aito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated withincancer cell nests as a prognostic factor in human colorectalcancer. Cancer Res. 1998;58:3491-3494.